Abstract
A higher risk of thromboembolic events (TEE) has been recently reported in patients (pts) with non-small-cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements (incidence rate 20-30%). BRAF mutations have been described in 4% of NSCLC. Whether pts with BRAF mutant NSCLC show higher risk of TEE is unknown. We aimed to describe the incidence, characteristics and time of onset of TEE in pts with advanced BRAF mutant NSCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
